ALGS Q4 2022 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+863.8% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$23M-641.3% margin

Net Income

-$22M-618.8% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-13.9%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$147M

Total Liabilities

$43M

Stockholders' Equity

$104M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$367,000	+863.8%
Gross Profit	$4M	$367,000	+863.8%
Operating Income	-$23M	-$38M	+40.2%
Net Income	-$22M	-$38M	+42.0%